The Semaglutide Smackdown: Delhi HC Calls Out Big Pharma's Evergreening Playbook, But Punishes Dr. Reddy's for Not "Clearing the Way"

The Hook: Why This Case Matters Right Now

If you practice IP law in India, you already know that the "Genus vs. Species" patent battle is the defining pharmaceutical litigation trend of our decade. But when the drug in question is Semaglutide—the active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss drugs Ozempic and Wegovy—the stakes transcend standard patent litigation. We are talking about billions of dollars and a global cultural phenomenon.

In Novo Nordisk AS v. Dr. Reddy's Laboratories (CS(COMM) 565/2025), decided on December 2, 2025, the Delhi High Court delivered a masterclass on the limits of patent monopolies. Justice Manmeet Pritam Singh Arora's judgment is a sharp, necessary rebuke to the practice of pharmaceutical "evergreening." Yet, in a fascinating twist of equitable relief, the Court still restricted the generic manufacturer because they failed to follow a cardinal procedural rule: clearing the way. For patent litigators, this 99-page judgment is mandatory reading on how substantive patent invalidity can still be kneecapped by procedural arrogance.

The Facts: Stripped to the Essentials

Let's cut through the noise. Novo Nordisk holds Indian Patent No. 262697 (the "Suit Patent" or "IN'697") covering the Semaglutide compound. This patent expires imminently on March 20, 2026. Semaglutide is a breakthrough GLP-1 analogue because its massive half-life allows for once-a-week subcutaneous injections, unlike older drugs that required daily dosing.

In late 2024, Novo discovered that Dr. Reddy's and OneSource (the Defendants) were gearing up to manufacture and export Semaglutide from India. Dr. Reddy's formally commenced manufacturing in April 2025. Novo immediately filed for an interim injunction to halt them.

The catch? Novo previously held an older patent, IN'275964 (the "Genus Patent" or "IN'964"), which expired in September 2024. This older patent broadly covered a massive group of GLP-1 analogues. The Defendants argued that Semaglutide was inherently covered by this expired Genus Patent, and the newer Suit Patent was merely an illegal extension of Novo's monopoly.

The Arguments: The Clash of Titans

Novo Nordisk's Case: Novo argued that Semaglutide is a highly inventive "species" that was never explicitly disclosed in the expired Genus Patent. They leaned heavily on the drug's phenomenal therapeutic efficacy (a 165-hour half-life in humans). Relying on the Division Bench ruling in F. Hoffmann-La Roche v. Cipla Ltd. (2015 SCC OnLine Del 13619), Novo argued that fulfilling a "long-felt need" establishes an inventive step. They accused Dr. Reddy's of using "hindsight reconstruction" to piece together Semaglutide from the thousands of possible combinations in the Genus Patent.

Dr. Reddy's Defence: Led by heavyweights Mr. Gopal Subramanium and Mr. J. Sai Deepak, the Defendants ran a textbook Section 64 and Section 3(d) defence. They argued that Semaglutide is structurally identical to "Example 61" of the expired Genus Patent, with just one minor amino acid substitution (replacing 'Ala' with 'Aib' at the 8th position). Because the inventors of both patents were the same "persons in the know," this substitution was glaringly obvious. Furthermore, they brought the receipts: Novo had sought Patent Term Extensions (PTEs) in foreign jurisdictions for Semaglutide based on the Genus patent and filed a single Form 27 (statement of working) in India clubbing both patents together. This, the Defendants argued, was a fatal admission of prior claiming under Section 64(1)(a) of the Patents Act, 1970.

The Judgment: A Split Decision on Law and Equity

Justice Arora's analysis is meticulous. On the substantive patent law, the Court sided completely with Dr. Reddy's. The Court found a strong prima facie case that the Suit Patent was invalid due to prior claiming (Section 64(1)(a)) and obviousness (Section 64(1)(f)).

The Court observed:

"The Court infers that the Plaintiff invented the Semaglutide compound in 2004, which is contemporaneous to the time of filing the Genus Patent IN'964, but wilfully withheld the Semaglutide compound from the Patent Office and artificially created a second patent... to extend the monopoly already granted."

The Court held that the substitution of 'Aib' at the 8th position was a known technique to increase half-life, making it obvious to a "person in the know." Consequently, the Court refused to grant the interim injunction to Novo Nordisk.

However, the Court did not let Dr. Reddy's off the hook entirely. Applying the principle from Merck Sharp and Dohme Corp v. Glenmark Pharmaceuticals (2015 SCC OnLine Del 8227), the Court noted that Dr. Reddy's started manufacturing in April 2025 without first filing a revocation petition to invalidate the Suit Patent. Because they failed to "clear the way," the Court bound Dr. Reddy's to a strict undertaking: they are permitted to manufacture and export to countries where Novo lacks a patent, but they are absolutely barred from selling Semaglutide in India until the Suit Patent expires in March 2026.

The Critique: Right on the Science, Contradictory on the Equity?

As a legal analyst, I have to say Justice Arora's handling of the evergreening issue is spot-on. The Indian patent regime, fortified by Section 3(d) and the Supreme Court's landmark Novartis ruling, is explicitly designed to prevent Big Pharma from staggering their patent filings to secure 40 years of exclusivity for a single inventive concept. Novo's attempt to distance Semaglutide from its own Genus Patent fell apart the moment the Court reviewed Novo's own Form 27s and foreign PTE applications. You simply cannot tell foreign patent offices that Semaglutide is covered by the Genus Patent to secure extensions there, and then tell the Indian Patent Office that it is a completely distinct invention to survive a Section 64 challenge here. The Court rightly punished this hypocrisy.

However, the equitable relief feels slightly contradictory. If the Court has returned a strong prima facie finding that the Suit Patent is an illegal evergreening tactic—essentially a fraud on the patent bargain—why protect Novo's domestic market until March 2026? Restricting Dr. Reddy's from selling in India purely because of "procedural mala fides" (not clearing the way) arguably elevates procedure over public interest. If a life-saving diabetes drug is locked behind an invalid patent, the public suffers the high costs.

That being said, one must admire the tactical brilliance of Dr. Reddy's legal team. Realizing that the "clearing the way" doctrine was their Achilles' heel, they made a sharp strategic concession early on: offering an undertaking not to sell in India, but reserving the right to export. This neutralized the threat of a blanket injunction, protecting their massive Rs. 1,000 crore manufacturing investment while keeping their export pipelines open.

The Takeaway: Lessons for Practitioners

For Indian patent lawyers, this judgment serves two brutal, practical lessons:

1. For Patentees: Your Regulatory Filings Are Your Own Worst Enemy.
If you are representing a multinational pharmaceutical company, you must audit their global prosecution history and local Form 27 filings. Justice Arora heavily relied on Novo's Form 27 declarations and foreign PTEs to establish prior claiming. You cannot speak from both sides of your mouth across different jurisdictions. The Indian courts are watching what you file in Europe, the US, and Japan.

2. For Generics: "Clearing the Way" is Mandatory, Not Optional.
If you advise a generic manufacturer, you must drill this into their commercial teams: Do not launch at risk without filing a revocation suit first. Even if you have a bulletproof invalidity defence—even if you can prove evergreening beyond a shadow of a doubt—if you launch your product while the patent is on the register without challenging it first, the Delhi High Court will restrain you. Procedural hygiene is just as important as substantive patent law.

Ultimately, Novo Nordisk v. Dr. Reddy's is a sophisticated balancing act. It protects the integrity of the Indian patent system against evergreening, while maintaining commercial discipline among generic challengers. As Semaglutide continues to dominate global headlines, this judgment ensures that India remains a fierce, but rule-bound, battleground for pharmaceutical innovation.